FY2025 Earnings Forecast for ENTA Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2025 earnings per share estimate for Enanta Pharmaceuticals from ($4.69) to ($4.16), maintaining a "Buy" rating and a price target of $20.00.
• The biotechnology company reported a quarterly earnings beat with ($0.85) earnings per share, outperforming the consensus estimate of ($1.25), alongside a revenue of $18.31 million.
• Various institutional investors have increased their stakes in Enanta Pharmaceuticals, with hedge funds now owning 94.99% of the company's stock.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst B. Folkes now forecasts that the biotechnology company will post earnings of ($4.16) per share for the year, up from their previous forecast of ($4.69). HC Wainwright currently has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q4 2025 earnings at ($1.19) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.12) EPS and FY2029 earnings at ($2.11) EPS.

A number of other analysts have also issued reports on the company. JMP Securities boosted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a report on Tuesday, August 12th. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $21.67.

Enanta Pharmaceuticals Stock Up 1.8%

ENTA stock traded up $0.1450 during trading on Thursday, hitting $8.3150. The company had a trading volume of 158,514 shares, compared to its average volume of 281,560. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $13.43. The company has a 50 day simple moving average of $7.41 and a 200-day simple moving average of $6.53. The firm has a market capitalization of $177.76 million, a P/E ratio of -1.94 and a beta of 0.88.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The company had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,779 shares during the period. US Bancorp DE purchased a new stake in Enanta Pharmaceuticals during the first quarter worth $36,000. Tower Research Capital LLC TRC grew its position in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares during the period. GAMMA Investing LLC purchased a new position in Enanta Pharmaceuticals in the first quarter valued at $40,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Enanta Pharmaceuticals in the second quarter worth about $88,000. Institutional investors and hedge funds own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.